Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells $20,809.75 in Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 6,403 shares of the stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $3.25, for a total value of $20,809.75. Following the sale, the insider now owns 1,249,327 shares in the company, valued at $4,060,312.75. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, May 1st, Aladar Szalay sold 33,061 shares of Genelux stock. The shares were sold at an average price of $3.30, for a total value of $109,101.30.
• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The shares were sold at an average price of $3.50, for a total value of $28,224.00.
• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Price Performance

NASDAQ GNLX opened at $3.83 on Friday. The firm has a 50-day moving average price of $5.34 and a two-hundred day moving average price of $10.26. Genelux Co. has a 12-month low of $3.06 and a 12-month high of $40.98.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Friday, March 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.04). On average, research analysts predict that Genelux Co. will post -0.81 EPS for the current year.

Institutional Trading of Genelux

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Genelux during the third quarter worth about $162,000. Bank of New York Mellon Corp boosted its holdings in shares of Genelux by 476.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 53,938 shares of the company’s stock valued at $1,321,000 after purchasing an additional 44,584 shares in the last quarter. LifeSteps Financial Inc. lifted its position in shares of Genelux by 145.3% during the 3rd quarter. LifeSteps Financial Inc. now owns 32,817 shares of the company’s stock worth $804,000 after buying an additional 19,438 shares during the last quarter. Whittier Trust Co. acquired a new position in Genelux during the third quarter worth about $175,000. Finally, Aspen Investment Management Inc acquired a new position in Genelux during the 3rd quarter worth approximately $290,000. 37.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. HC Wainwright cut their price objective on shares of Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Benchmark reissued a “speculative buy” rating and set a $30.00 price target on shares of Genelux in a report on Wednesday, April 3rd.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.